Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge M Haeck

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|February 5, 2025
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitisLisa P van der Rijst, Nienke Veldhuis, Sara van der Kamp, et al.
Expert Opinion on Biological Therapy|December 1, 2025
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatmentCeleste M Boesjes, Lian F van der Gang, Roselie E Achten, et al.
Journal of the American Academy of Dermatology|August 17, 2010
Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitisJohanna M Kwakkel-van Erp, Inge M Haeck, Annelieke W M Paantjens, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Bone mineral density in children with moderate to severe atopic dermatitisSara Gertrudes Anna van Velsen, Mirjam J Knol, Rachel L A van Eijk, et al.
The British Journal of Dermatology|May 13, 2023
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registryLotte S Spekhorst, Celeste M Boesjes, Laura Loman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2026
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDayLian F van der Gang, Nicolaas P A Zuithoff, Inge M Haeck, et al.
American Journal of Clinical Dermatology|May 27, 2024
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis TreatmentSarah E Thomas, Marieke M B Seyger, Josje E Mangnus, et al.
Acta Dermato-Venereologica|June 19, 2025
Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of PsoriasisLinda T H Godding, Marieke M B Seyger, Albert Duvetorp, et al.
Journal of Psoriasis and Psoriatic Arthritis|April 4, 2025
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE RegistryLiana Barenbrug, Renate G van der Molen, Jake S F Maurits, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|February 5, 2025
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitisLisa P van der Rijst, Nienke Veldhuis, Sara van der Kamp, et al.
Expert Opinion on Biological Therapy|December 1, 2025
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatmentCeleste M Boesjes, Lian F van der Gang, Roselie E Achten, et al.
Journal of the American Academy of Dermatology|August 17, 2010
Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitisJohanna M Kwakkel-van Erp, Inge M Haeck, Annelieke W M Paantjens, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Bone mineral density in children with moderate to severe atopic dermatitisSara Gertrudes Anna van Velsen, Mirjam J Knol, Rachel L A van Eijk, et al.
The British Journal of Dermatology|May 13, 2023
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registryLotte S Spekhorst, Celeste M Boesjes, Laura Loman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2026
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDayLian F van der Gang, Nicolaas P A Zuithoff, Inge M Haeck, et al.
American Journal of Clinical Dermatology|May 27, 2024
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis TreatmentSarah E Thomas, Marieke M B Seyger, Josje E Mangnus, et al.
Acta Dermato-Venereologica|June 19, 2025
Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of PsoriasisLinda T H Godding, Marieke M B Seyger, Albert Duvetorp, et al.
Journal of Psoriasis and Psoriatic Arthritis|April 4, 2025
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE RegistryLiana Barenbrug, Renate G van der Molen, Jake S F Maurits, et al.
Pageof 2